333 related articles for article (PubMed ID: 30012349)
21. Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells.
Doig CL; Battaglia S; Khanim FL; Bunce CM; Campbell MJ
J Steroid Biochem Mol Biol; 2016 Jan; 155(Pt A):47-55. PubMed ID: 26429394
[TBL] [Abstract][Full Text] [Related]
22. Reversal of Apalutamide and Darolutamide Aldo-Keto Reductase 1C3-Mediated Resistance by a Small Molecule Inhibitor.
Morsy A; Trippier PC
ACS Chem Biol; 2020 Mar; 15(3):646-650. PubMed ID: 32125151
[TBL] [Abstract][Full Text] [Related]
23. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors.
Penning TM; Steckelbroeck S; Bauman DR; Miller MW; Jin Y; Peehl DM; Fung KM; Lin HK
Mol Cell Endocrinol; 2006 Mar; 248(1-2):182-91. PubMed ID: 16417966
[TBL] [Abstract][Full Text] [Related]
24. Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer.
Liedtke AJ; Adeniji AO; Chen M; Byrns MC; Jin Y; Christianson DW; Marnett LJ; Penning TM
J Med Chem; 2013 Mar; 56(6):2429-46. PubMed ID: 23432095
[TBL] [Abstract][Full Text] [Related]
25. Hydroxytriazole derivatives as potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitors discovered by bioisosteric scaffold hopping approach.
Pippione AC; Giraudo A; Bonanni D; Carnovale IM; Marini E; Cena C; Costale A; Zonari D; Pors K; Sadiq M; Boschi D; Oliaro-Bosso S; Lolli ML
Eur J Med Chem; 2017 Oct; 139():936-946. PubMed ID: 28881288
[TBL] [Abstract][Full Text] [Related]
26. Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor.
Adeniji A; Uddin MJ; Zang T; Tamae D; Wangtrakuldee P; Marnett LJ; Penning TM
J Med Chem; 2016 Aug; 59(16):7431-44. PubMed ID: 27486833
[TBL] [Abstract][Full Text] [Related]
27. Screening baccharin analogs as selective inhibitors against type 5 17β-hydroxysteroid dehydrogenase (AKR1C3).
Zang T; Verma K; Chen M; Jin Y; Trippier PC; Penning TM
Chem Biol Interact; 2015 Jun; 234():339-48. PubMed ID: 25555457
[TBL] [Abstract][Full Text] [Related]
28. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
[TBL] [Abstract][Full Text] [Related]
29. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.
Fung KM; Samara EN; Wong C; Metwalli A; Krlin R; Bane B; Liu CZ; Yang JT; Pitha JV; Culkin DJ; Kropp BP; Penning TM; Lin HK
Endocr Relat Cancer; 2006 Mar; 13(1):169-80. PubMed ID: 16601286
[TBL] [Abstract][Full Text] [Related]
30. Novel aldo-keto reductase 1C3 inhibitor affects androgen metabolism but not ovarian function in healthy women: a phase 1 study.
Gashaw I; Reif S; Wiesinger H; Kaiser A; Zollmann FS; Scheerans C; Grevel J; Piraino P; Seidel H; Peters M; Rottmann A; Rohde B; Arlt W; Hilpert J
Eur J Endocrinol; 2023 Jul; 188(7):578-591. PubMed ID: 37306288
[TBL] [Abstract][Full Text] [Related]
31. In situ proteolysis of an N-terminal His tag with thrombin improves the diffraction quality of human aldo-keto reductase 1C3 crystals.
Plavša JJ; Řezáčová P; Kugler M; Pachl P; Brynda J; Voburka Z; Ćelić A; Petri ET; Škerlová J
Acta Crystallogr F Struct Biol Commun; 2018 May; 74(Pt 5):300-306. PubMed ID: 29717998
[TBL] [Abstract][Full Text] [Related]
32. Tissue distribution of human AKR1C3 and rat homolog in the adult genitourinary system.
Azzarello J; Fung KM; Lin HK
J Histochem Cytochem; 2008 Sep; 56(9):853-61. PubMed ID: 18574251
[TBL] [Abstract][Full Text] [Related]
33. Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3).
Penning TM; Burczynski ME; Jez JM; Lin HK; Ma H; Moore M; Ratnam K; Palackal N
Mol Cell Endocrinol; 2001 Jan; 171(1-2):137-49. PubMed ID: 11165022
[TBL] [Abstract][Full Text] [Related]
34. Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma.
Miller VL; Lin HK; Murugan P; Fan M; Penning TM; Brame LS; Yang Q; Fung KM
Int J Clin Exp Pathol; 2012; 5(4):278-89. PubMed ID: 22670171
[TBL] [Abstract][Full Text] [Related]
35. Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.
Hamid AR; Pfeiffer MJ; Verhaegh GW; Schaafsma E; Brandt A; Sweep FC; Sedelaar JP; Schalken JA
Mol Med; 2013 Jan; 18(1):1449-55. PubMed ID: 23196782
[TBL] [Abstract][Full Text] [Related]
36. Aldo-keto reductase 1C3-Assessment as a new target for the treatment of endometriosis.
Rižner TL; Penning TM
Pharmacol Res; 2020 Feb; 152():104446. PubMed ID: 31546014
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation.
Sun SQ; Gu X; Gao XS; Li Y; Yu H; Xiong W; Yu H; Wang W; Li Y; Teng Y; Zhou D
Oncotarget; 2016 Jul; 7(30):48050-48058. PubMed ID: 27385003
[TBL] [Abstract][Full Text] [Related]
38. New aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the hydroxytriazole scaffold.
Pippione AC; Kilic-Kurt Z; Kovachka S; Sainas S; Rolando B; Denasio E; Pors K; Adinolfi S; Zonari D; Bagnati R; Lolli ML; Spyrakis F; Oliaro-Bosso S; Boschi D
Eur J Med Chem; 2022 Jul; 237():114366. PubMed ID: 35447434
[TBL] [Abstract][Full Text] [Related]
39. Expression of aldo-keto reductase family 1 member C3 (AKR1C3) in neuroendocrine tumors & adenocarcinomas of pancreas, gastrointestinal tract, and lung.
Chang TS; Lin HK; Rogers KA; Brame LS; Yeh MM; Yang Q; Fung KM
Int J Clin Exp Pathol; 2013; 6(11):2419-29. PubMed ID: 24228104
[TBL] [Abstract][Full Text] [Related]
40. Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile.
Novotná E; Büküm N; Hofman J; Flaxová M; Kouklíková E; Louvarová D; Wsól V
Arch Toxicol; 2018 Sep; 92(9):2845-2857. PubMed ID: 29992508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
